- Home
- BTM vs MIRA Comparison
BTM vs MIRA Comparison
Compare BTM & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BTM | MIRA |
|---|---|---|
| Founded | 2016 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.0M | 33.7M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | BTM | MIRA |
|---|---|---|
| Price | $1.42 | $1.51 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $6.25 | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 222.6K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $635,643,000.00 | N/A |
| Revenue This Year | $7.87 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $5.24 | ★ N/A |
| Revenue Growth | ★ 8.61 | N/A |
| 52 Week Low | $0.93 | $0.73 |
| 52 Week High | $6.88 | $2.45 |
Technical Indicators
Market Signals| Indicator | BTM | MIRA |
|---|---|---|
| Relative Strength Index (RSI) | 33.39 | 53.64 |
| Support Level | $1.29 | $1.41 |
| Resistance Level | $1.69 | $1.50 |
| Average True Range (ATR) | 0.12 | 0.07 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 32.50 | 75.00 |
Price Performance
Historical ComparisonAbout BTM Bitcoin Depot Inc.
Bitcoin Depot Inc owns and operates the widest network of BTMs across North America where customers can buy and sell Bitcoin. Bitcoin Depot helps power the digital economy for users of cash. It has locations across the U.S. and Canada at, among others, the following types of retailers: Convenience Stores and Gas Station Chains, Pharmacies and Grocers and Mall Operators.
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.